期刊文献+

顺铂经支气管动脉灌注——临床药代动力学规律的初步研究 被引量:1

A preliminary study on the pharmacokinetics of Cisplatin after bronchial arterial infusion (BAI)
暂未订购
导出
摘要 6例晚期肺癌病人经支气管动脉灌注(BAI)顺铂,另2例经肘静脉灌注顺铂。取血样后用极谱法测定顺铂的血药浓度,行药代动力学分析。结果表明顺铂两种方式给药,药代动力学均表现为二房室模型。经支气管动脉注药病人血液中游离铂的浓度高于经静脉注药病人血中的浓度,前者血中游离铂的消除相半衰期也长于后者。文章讨论了这种差异可能的原因及其临床意义。 Cisplatin was infused into bronchial artery (BAI) in six patients with advanced lung cancer and into median cubital vein in other two patients. The concentration of cisplatin in blood was determined by polarographic method for pharmacokinetic study of the agent. The blood drug--time curves of ofter infusing cisplatin by different route. were conformed to two-conpartment open model. The concentration of free cisplatin in plasma of patients after BAI was higher than that of patients after intravenous infusion, and the terminal half life period (t1/2β) is longer in patients by BAI than that in petients infused by vein.
出处 《现代诊断与治疗》 CAS 1992年第2期199-202,共4页 Modern Diagnosis and Treatment
关键词 顺铂 肺肿瘤 药代动力学 BAI Cisplatin Lung cancer Bronchial artery infusion (BAI) Pharmacokinetics
  • 相关文献

参考文献1

  • 1L. Hegedüs,W. J. F. Vijgh,I. Klein,S. Kerpel-Fronius,H. M. Pinedo. Chemical reactivity of cisplatin bound to human plasma proteins[J] 1987,Cancer Chemotherapy and Pharmacology(3):211~212

同被引文献22

  • 1彭彬,Bodd.,AV.卡铂与顺铂的小儿临床药动学及药效学研究进展及剂量方案[J].癌症,1995,14(6):469-472. 被引量:2
  • 2刘宝庆,隋因,牛劲松,夏东亚,高艳,陈萍.环磷酰胺、阿霉素、顺铂联合用药与单一用药药动学的比较[J].中国药学杂志,1995,30(8):479-482. 被引量:7
  • 3邓成艳,黄荣丽,连利娟,宋鸿钊.大剂量顺铂腹腔化疗的药代动力学研究[J].中华妇产科杂志,1996,31(3):159-162. 被引量:16
  • 4孙秀丽,李小平,王建六,魏丽惠.子宫内膜癌术中区域性动脉灌注化疗的研究[J].现代妇产科进展,2006,15(6):415-418. 被引量:3
  • 5唐棣华.抗癌药物顺铂抗癌机制的线索[J].化学研究与应用,2000,12(1):96.
  • 6Wakelee HA, Middleton G, Dunlop D, et al. A phase I pharmacoki- netic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer ( NSCLC ) [ J ]. Cancer Chemother Pharmacol,2012,69(3) :815-824.
  • 7Delord JP,Puozzo C, Lefresne F, et al. Combination chemotherapy of vinorelbine and cisplatin : a phase I pharmacokinetic study in pa- tients with metastatic solid tumors [ J ]. Anticancer Res, 2009,29 (2) :553-560.
  • 8Goss G, Shepherd FA, Laurie S, et al. A phase I and pharmacoki- netic study of daily oral cediranib, an inhibitor of vascular endothe- lial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group[J]. Eur J Cancer,2009,45(5) :782-788.
  • 9Biro K,Noszek L,Prekopp P,et al. Characteristics and risk factors of cisplatin-induced ototoxity in testicular cancer patients detected by distorsion product otoacoustic emission [ J ]. Oncology, 2006,70 (3) :177-184.
  • 10Teranishi M, Nakashima T, Wakabayashi T. Effect of alpha-to- copherol on cisplatin-induced ototoxicity in guinea pigs [ J ]. Hear Res.2001.151 (1/2) :61-70.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部